Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST_TX: Heterologous vs Homologous 3rd COVID-19 Vaccine in Kidney Transplant Recipients
NCT05324319Phase 2Unknown
- Sponsor
- Medical University of Vienna
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Viral Vector Vaccines, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Ad26.COV2.S and ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Seroconversion at 4 weeks. Status: unknown.
02
Drugs
Ad26.COV2.SChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05324319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324319.